These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 21912473)

  • 41. [Efficacy and tolerability of pantoprazole in the treatment of gastroesophageal reflux disease].
    Gillessen A
    MMW Fortschr Med; 2010 Apr; 152 Suppl 1():21-9. PubMed ID: 20942304
    [TBL] [Abstract][Full Text] [Related]  

  • 42. How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related?
    de Bortoli N; Nacci A; Savarino E; Martinucci I; Bellini M; Fattori B; Ceccarelli L; Costa F; Mumolo MG; Ricchiuti A; Savarino V; Berrettini S; Marchi S
    World J Gastroenterol; 2012 Aug; 18(32):4363-70. PubMed ID: 22969200
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.
    Komatsu-Tanaka M; Iwakiri R; Fujimoto K; Fujiwara Y; Inamori M; Tanaka J; Shimatani T; Akiyama J; Ando T; Manabe N; Kinjo F; Deguchi R; Kusano M
    Dig Endosc; 2012 Nov; 24(6):407-11. PubMed ID: 23078431
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The characteristics of gastroesophageal reflux disease overlapping with functional bowel diseases in gastrointestinal clinic].
    Jiang X; Lü FF; Wang WC; Liu YL
    Zhonghua Nei Ke Za Zhi; 2013 Oct; 52(10):806-10. PubMed ID: 24378054
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nondigestive symptoms in non-erosive reflux disease: nature, prevalence and relation to acid reflux.
    Hershcovici T; Zimmerman J
    Aliment Pharmacol Ther; 2008 Nov; 28(9):1127-33. PubMed ID: 18702676
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of pantoprazole on duodeno-gastro-esophageal reflux (DGER).
    Kunsch S; Neesse A; Linhart T; Steinkamp M; Fensterer H; Adler G; Gress TM; Ellenrieder V
    Z Gastroenterol; 2009 Mar; 47(3):277-82. PubMed ID: 19280541
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome.
    Kountouras J; Chatzopoulos D; Zavos C; Boura P; Venizelos J; Kalis A
    Hepatogastroenterology; 2002; 49(43):193-7. PubMed ID: 11941952
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Demographic, clinical, and psychological characteristics of the heartburn groups classified using the Rome III criteria and factors associated with the responsiveness to proton pump inhibitors in the gastroesophageal reflux disease group.
    Lee KJ; Kwon HC; Cheong JY; Cho SW
    Digestion; 2009; 79(3):131-6. PubMed ID: 19307735
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease.
    Kobeissy AA; Hashash JG; Jamali FR; Skoury AM; Haddad R; El-Samad S; Ladki R; Aswad R; Soweid AM
    World J Gastroenterol; 2012 May; 18(19):2390-5. PubMed ID: 22654431
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ; Salas M; Ward A
    Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gastroesophageal reflux disease as an etiology of sleep disturbance in subjects with insomnia and minimal reflux symptoms: a pilot study of prevalence and response to therapy.
    Shaheen NJ; Madanick RD; Alattar M; Morgan DR; Davis PH; Galanko JA; Spacek MB; Vaughn BV
    Dig Dis Sci; 2008 Jun; 53(6):1493-9. PubMed ID: 17985241
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical, metabolic, and psychological characteristics in patients with gastroesophageal reflux disease overlap with irritable bowel syndrome.
    Hsu CS; Liu TT; Wen SH; Wang CC; Yi CH; Chen JH; Lei WY; Orr WC; Fabio P; Chen CL
    Eur J Gastroenterol Hepatol; 2015 May; 27(5):516-22. PubMed ID: 25822860
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group.
    Richter JE; Bochenek W
    Am J Gastroenterol; 2000 Nov; 95(11):3071-80. PubMed ID: 11095320
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term management of GERD in the elderly with pantoprazole.
    Calabrese C; Fabbri A; Di Febo G
    Clin Interv Aging; 2007; 2(1):85-92. PubMed ID: 18044079
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Distinct clinical characteristics between patients with nonerosive reflux disease and those with reflux esophagitis.
    Wu JC; Cheung CM; Wong VW; Sung JJ
    Clin Gastroenterol Hepatol; 2007 Jun; 5(6):690-5. PubMed ID: 17481961
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study.
    Goh KL; Benamouzig R; Sander P; Schwan T;
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):205-11. PubMed ID: 17301646
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease.
    Scholten T; Teutsch I; Bohuschke M; Gatz G
    Clin Drug Investig; 2007; 27(4):287-96. PubMed ID: 17358101
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease].
    Liu XH; Ke MY; Song ZQ; Luo JY; Yuan YZ; Hou XH; Zhu YL; Sun J; Zha H
    Zhonghua Nei Ke Za Zhi; 2005 Nov; 44(11):818-21. PubMed ID: 16316559
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial.
    Madan K; Ahuja V; Kashyap PC; Sharma MP
    Dis Esophagus; 2004; 17(4):274-8. PubMed ID: 15569362
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease.
    Niu XP; Yu BP; Wang YD; Han Z; Liu SF; He CY; Zhang GZ; Wu WC
    World J Gastroenterol; 2013 May; 19(20):3124-9. PubMed ID: 23716993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.